These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 26821781)

  • 1. Reduced duration of untreated illness over time in patients with schizophrenia spectrum, mood and anxiety disorders.
    Dell'Osso B; Oldani L; Camuri G; Benatti B; Grancini B; Arici C; Cremaschi L; Palazzo M; Spagnolin G; Dobrea C; Altamura AC
    Psychiatry Clin Neurosci; 2016 May; 70(5):202-10. PubMed ID: 26821781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Access and latency to first antipsychotic treatment in Italian patients with schizophrenia and other schizophrenic spectrum disorders across different epochs.
    Palazzo MC; Arici C; Dell'Osso B; Cremaschi L; Grancini B; Camuri G; Benatti B; Oldani L; Dobrea C; Cattaneo A; Altamura AC
    Hum Psychopharmacol; 2016 Mar; 31(2):113-20. PubMed ID: 26948428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors characterizing access and latency to first pharmacological treatment in Italian patients with schizophrenia, mood, and anxiety spectrum disorders.
    Dell'Osso B; Cremaschi L; Palazzo C; Suardi N; Spagnolin G; Camuri G; Benatti B; Oldani L; Dobrea C; Arici C; Pace G; Tiseo A; Nahum ES; Castellano F; D'Urso N; Clerici M; Primavera D; Carpiniello B; Altamura AC
    Int Clin Psychopharmacol; 2015 Jan; 30(1):29-35. PubMed ID: 25117878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age at onset and latency to treatment (duration of untreated illness) in patients with mood and anxiety disorders: a naturalistic study.
    Altamura AC; Buoli M; Albano A; Dell'Osso B
    Int Clin Psychopharmacol; 2010 May; 25(3):172-9. PubMed ID: 20305566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in latency to first pharmacological treatment (duration of untreated illness) in anxiety disorders: a study on patients with panic disorder, generalized anxiety disorder and obsessive-compulsive disorder.
    Dell'Osso B; Camuri G; Benatti B; Buoli M; Altamura AC
    Early Interv Psychiatry; 2013 Nov; 7(4):374-80. PubMed ID: 23347385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Italian patients with more recent onset of Major Depressive Disorder have a shorter duration of untreated illness.
    Dell'Osso B; Cremaschi L; Grancini B; De Cagna F; Benatti B; Camuri G; Arici C; Dobrea C; Oldani L; Palazzo MC; Vismara M; Altamura AC
    Int J Clin Pract; 2017 Feb; 71(2):. PubMed ID: 28090727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Understanding the role of the duration of untreated illness in psychiatric disorders: a narrative review].
    Altamura AC; Camuri G; Dell'Osso B
    Riv Psichiatr; 2010; 45(4):197-208. PubMed ID: 20942365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of untreated illness (DUI) and schizophrenia sub-types: a collaborative study between the universities of Milan and Moscow.
    Buoli M; Dell'osso B; Zaytseva Y; Gurovich IY; Movina L; Dorodnova A; Shmuckler A; Altamura AC
    Int J Soc Psychiatry; 2013 Dec; 59(8):765-70. PubMed ID: 23034286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of untreated illness and duration of illness in anxiety disorders: assessment and influence on outcome.
    Altamura AC; Camuri G; Dell'Osso B
    Mod Trends Pharmacopsychiatry; 2013; 29():111-8. PubMed ID: 25225021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does initial use of benzodiazepines delay an adequate pharmacological treatment? A multicentre analysis in patients with psychotic and affective disorders.
    Grancini B; De Carlo V; Palazzo M; Vismara M; Arici C; Cremaschi L; Benatti B; Altamura AC; Dell'Osso B
    Int Clin Psychopharmacol; 2018 May; 33(3):140-146. PubMed ID: 29461302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of comorbidities in duration of untreated illness for bipolar spectrum disorders.
    Murru A; Primavera D; Oliva M; Meloni ML; Vieta E; Carpiniello B
    J Affect Disord; 2015 Dec; 188():319-23. PubMed ID: 26408989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Early signs and symptoms before the psychotic onset. A study on the Duration of Untreated Illness (DUI) in a sample of patients with diagnosis of "non-affective psychotic disorders"].
    Bensi M; Armando M; Censi V; Aiello D; Fortes Lindau J; Cavaggioni G; Birchwood M; Fiori Nastro P
    Clin Ter; 2011; 162(1):11-8. PubMed ID: 21448540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anxiety disorders in private practice psychiatric out-patients: prevalence, comorbidity and burden (DELTA study)].
    Pélissolo A; André C; Chignon JM; Dutoit D; Martin P; Richard-Berthe C; Tignol J
    Encephale; 2002; 28(6 Pt 1):510-9. PubMed ID: 12506263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Under-recognition and under-treatment of DSM-IV classified mood and anxiety disorders among disability claimants.
    Cornelius B; van der Klink JJ; Brouwer S; Groothoff JW
    Disabil Rehabil; 2014; 36(14):1161-8. PubMed ID: 24024541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Early course of illness in first episode schizophrenia with long duration of untreated illness - a comparative study].
    Köhn D; Niedersteberg A; Wieneke A; Bechdolf A; Pukrop R; Ruhrmann S; Schultze-Lutter F; Maier W; Klosterkötter J
    Fortschr Neurol Psychiatr; 2004 Feb; 72(2):88-92. PubMed ID: 14770348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duration of untreated illness as a predictor of treatment response and clinical course in generalized anxiety disorder.
    Altamura AC; Dell'osso B; D'Urso N; Russo M; Fumagalli S; Mundo E
    CNS Spectr; 2008 May; 13(5):415-22. PubMed ID: 18496479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in duration of untreated illness, duration, and severity of illness among clinical phenotypes of obsessive-compulsive disorder.
    Dell'Osso B; Benatti B; Oldani L; Spagnolin G; Altamura AC
    CNS Spectr; 2015 Oct; 20(5):474-8. PubMed ID: 24967664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of mood and anxiety disorders in the community: results from the Israel National Health Survey.
    Levinson D; Zilber N; Lerner Y; Grinshpoon A; Levav I
    Isr J Psychiatry Relat Sci; 2007; 44(2):94-103. PubMed ID: 18080646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variables associated with disparities in treatment of patients with schizophrenia and comorbid mood and anxiety disorders.
    Dixon L; Green-Paden L; Delahanty J; Lucksted A; Postrado L; Hall J
    Psychiatr Serv; 2001 Sep; 52(9):1216-22. PubMed ID: 11533396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of anxiety disorders in the Finnish general population.
    Sihvo S; Hämäläinen J; Kiviruusu O; Pirkola S; Isometsä E
    J Affect Disord; 2006 Nov; 96(1-2):31-8. PubMed ID: 16797721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.